Why the study?
Pathogenic variants in RBM20 cause severe arrhythmogenic DCM, but the clinical course compared to other familial and non-familial forms of DCM required characterization.
Does RBM20 variant positivity predict earlier onset and worse clinical outcomes in dilated cardiomyopathy compared to TTNtv variants or idiopathic DCM?
Does RBM20 variant positivity predict earlier onset and worse clinical outcomes in dilated cardiomyopathy compared to TTNtv variants or idiopathic DCM?
Answers are grounded in this paper and cite their sources.
RBM20-mediated dilated cardiomyopathy is associated with a significantly earlier age of onset and a more aggressive clinical course, including earlier ventricular arrhythmias and advanced heart failure, compared to TTNtv-mediated and idiopathic DCM.
Disease-causative variants in RBM20-encoded RNA-binding motif protein 20 cause a severe arrhythmogenic dilated cardiomyopathy (DCM). We aimed to characterize the clinical course of RBM20-mediated DCM in comparison to other familial and non-familial forms of DCM. The Mayo Clinic Genetic Arrhythmogenic Cardiomyopathy (ACM) Registry was used to identify RBM20- and TTNtv-positive individuals. Additionally, patients with idiopathic non-ischemic DCM were included in this study. Ventricular arrhythmic (VA) events were defined as sustained ventricular arrhythmia, sudden cardiac arrest (SCA), or ventricular tachycardia (VT)/ventricular fibrillation (VF)-terminating implantable cardioverter defibrillator (ICD) therapy and advanced heart failure (AHF) events defined as ventricular assist device implantation or heart transplantation. Overall, we identified 43 RBM20- (49% female) and 108 TTNtv- positive individuals (44% female). RBM20 variant-positive individuals were younger at time of diagnosis at 31 years vs. 45 years old for TTNtv-positive individuals (p < 0.0001). Additionally, RBM20 variant-positive individuals were more likely to have a family history of SCA (67% vs. 30%; p < 0.0001) and cardiomyopathy (88% vs. 61%; p = 0.0008). Interestingly, the prevalence of AHF (14% vs. 5%) events was higher in RBM20 variant-positive patients. RBM20 variant-positive individuals had earlier times to both VA (p = 0.007) and AHF (p = 0.0008) events. Findings were similar in comparison to idiopathic DCM. In this single center study, RBM20 patients had an earlier progressing disease with a higher prevalence of advanced heart failure compared with TTNtv patients. RBM20 patients progressed to VA and AHF endpoints earlier.
No takes yet. Share an insight, caveat, or question.
Garmany et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: